Norges Bank
XLO icon

Norges Bank’s Xilio Therapeutics XLO Stock Holding History

Norges Bank’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,706
Closed -$356K – 2136
2022
Q2 		$356K Sell
8,706
-19,865
-70% -$1.05M ﹤0.01% 2020
2022
Q1 		$2.83M Hold
28,571
– – ﹤0.01% 1944
2021
Q4 		$6.4M Buy
+28,571
New +$6.81M ﹤0.01% 1873

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Norges Bank's XLO Position: Q3 2022 in Review

Norges Bank sold out of Xilio Therapeutics (XLO) in Q3 2022, closing a stake of 8,706 shares — an estimated $356K sold.

Norges Bank first reported a position in XLO in Q4 2021 and held it in 3 quarters. The position peaked at $6.4M in Q4 2021. 29 funds tracked by Wall St. Rank hold XLO as of Q3 2022.

  • Norges Bank reported no remaining Xilio Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Norges Bank sold 8,706 Xilio Therapeutics shares in Q3 2022, an estimated $356K.
  • Norges Bank first reported a position in Xilio Therapeutics in Q4 2021 and held it in 3 quarters.
  • Norges Bank's Xilio Therapeutics position peaked at $6.4M in Q4 2021.
  • 29 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2022.

Based on Norges Bank's 13F filing for Q3 2022, filed 14 Nov 2022.